Background. Lenalidomide is an immunomodulatory agent used to treat plasma cell dyscrasias. We previously observed worsening of kidney function in a high proportion of patients with AL amyloidosis during lenalidomide treatment. The objective of this study is to characterize alterations in kidney function among patients with AL amyloidosis undergoing treatment with lenalidomide. Methods. This is a secondary analysis of an ongoing clinical trial at a single referral centre. Forty-one patients with AL amyloidosis received lenalidomide with or without dexamethasone in monthly cycles. Kidney dysfunction was defined as ≥50% increase in serum creatinine. Severe kidney dysfunction was defined as ≥ 100% increase in serum creatinine. Recovery of renal function was defined as a return of serum creatinine to within 25% of the pretreatment value or discontinuation of dialysis. Results. Twenty-seven of 41 patients (66%) developed kidney dysfunction during lenalidomide treatment. The kidney dysfunction was severe in 13 of these patients (32%); four of whom required initiation of dialysis (10%). The median time to kidney dysfunction after starting lenalidomide was 44 days (interquartile range 15-108 days). Four of eight patients without underlying renal amyloidosis developed kidney dysfunction. Patients with severe kidney dysfunction were older and had a higher frequency of underlying renal amyloidosis, greater urinary protein excretion, and lower serum albumin. Recovery of renal function occurred in 12 patients (44%). Conclusions. Among patients with AL amyloidosis, worsening of kidney function occurs frequently during lenalidomide treatment. While a causal role of the drug has not been established, our findings suggest that kidney function should be monitored closely during treatment with this drug.
Introduction
Kidney involvement occurs in 50-80% of patients with AL amyloidosis and is characterized by nephrotic syndrome and progression to end-stage renal disease [1] . Current treatment approaches are targeted against clonal plasma cells, the source of the amyloidogenic immunoglobulin light chains. High-dose melphalan with autologous stem cell transplantation (HDM/SCT) can fully eradicate production of amyloidogenic light chains, improve function of affected organs, and decrease mortality [2, 3] . However, this aggressive approach is not effective for all patients and has significant toxicities that limit its use [4] . Melphalan administered orally with dexamethasone in repeated cycles, bortezomib, and lenalidomide are newer treatments that are being used increasingly for AL amyloidosis generally with less toxicity than HDM/SCT [5] [6] [7] [8] . Lenalidomide is an immunomodulatory agent that was initially developed as a treatment for multiple myeloma [9] [10] [11] [12] [13] . Early studies suggest that lenalidomide is also effective for AL amyloidosis, producing haematologic responses in 41-67% of patients [14, 15] .
The most frequent toxicities observed in early trials of lenalidomide for multiple myeloma were neutropaenia, thrombocytopaenia, anaemia and venous thromboembolic events [9] [10] [11] [12] [13] 16] . Kidney injury was not reported as an adverse event in these trials. However, a recent report by an author of the current paper together with investigators at another institution described five patients with plasma cell dyscrasias who developed acute renal failure during lenalidomide treatment [17] .
In an interim analysis of a phase 2 trial of lenalidomide for AL amyloidosis, we observed worsening of kidney function in 20 of 34 patients [14] . Information about timing, severity or reversibility of kidney dysfunction was not provided in the trial report. We now provide a detailed analysis of a larger group of trial participants in order to characterize the time course and reversibility of kidney dysfunction during lenalidomide treatment.
Materials and methods

Patients
As previously described, eligibility for the lenalidomide trial required (i) a tissue diagnosis of amyloidosis with evidence of an underlying clonal plasma cell dyscrasia by bone marrow biopsy, immunofixation electrophoresis of serum or urine or nephelometric serum free light chain assay, and (ii) no anti-plasma cell therapy for AL amyloidosis within the previous 4 weeks [14] . Trial enrolment began in March 2004 and was still ongoing at the time of this analysis. The study was approved by the Institutional Review Board of Boston University Medical Center in accordance with the Declaration of Helsinki, and all patients provided written informed consent. The trial is registered at ClinicalTrials.gov (NCT00091269). Patients were included in the current analysis if they enrolled before 17 September 2007, received lenalidomide for at least 1 week, and were not dialysis-dependent at the time of enrolment.
Data collection
Baseline clinical and laboratory data were collected prospectively. Glomerular filtration rate (GFR) and creatinine clearance were estimated using the standardized four-variable MDRD Study equation [18] and the Cockgroft-Gault formula [19] , respectively. Creatinine measurements performed at study visits were performed using the kinetic alkaline picrate assay calibrated to be traceable to an isotope dilution mass spectrometry (IDMS) reference. The normal range for this assay is 0.5-1.1 mg/dl. Amyloid organ involvement was defined using established criteria [20] . Patients were classified as having renal involvement if amyloid was present by kidney biopsy, or if either of the following was present in the absence of other known or suspected kidney disease: (i) urinary protein excretion >500 mg per 24 h or (ii) elevated serum creatinine concentration [20, 21] . Treatment-related data were obtained from a prospectively maintained clinical trial database and supplemented by medical record review. Possible aetiologies for alterations in kidney function including medications, infection, hypotension, congestive heart failure and other intercurrent medical events were recorded. Data abstraction from medical records was performed by a single individual.
Treatment protocol
Details of the treatment protocol have been previously reported [14] . The starting dose of lenalidomide was 25 mg per day. Because of poor tolerability (fatigue, lightheadedness, rash, deep venous thrombosis and creatinine elevation), the starting dose was decreased to 15 mg per day after the first eight patients in the trial (six of whom are included in this analysis) began treatment. The drug was administered for 21 of 28 days in repeated 28-day cycles. If there was no evidence of a haematologic response after three cycles, dexamethasone was added at doses of 10-20 mg per day on Days 1-4, 9-12 and 17-20 every other cycle. Treatment continued until there was evidence for disease progression or unacceptable toxicity. Reductions in dosage of lenalidomide or dexamethasone because of poor tolerability or adverse events were made as previously described [14] . Patients who experienced toxicities thought to be related to lenalidomide discontinued treatment until resolution of the event and then restarted treatment at the next lower dose level. Lenalidomide dose reductions were made in increments of 5 mg per day.
Outcome measures
Kidney function was ascertained from laboratory studies performed biweekly during each treatment cycle and weekly, or more often at the discretion of the treating physician, if an elevation in creatinine was observed. Kidney dysfunction was defined as an increase in serum creatinine of at least 50% from baseline. Severe kidney dysfunction was defined as an increase in serum creatinine concentration of at least 100% or the need for initiation of dialysis. Recovery of renal function was defined as a return of serum creatinine concentration to within 25% of the pre-treatment value or discontinuation of dialysis. Haematologic responses were defined according to published consensus criteria [20] . A complete response was defined as absence of monoclonal protein in the serum and urine by immunofixation electrophoresis, a normal bone marrow biopsy with <5% plasma cells and no predominance of kappa or lambda light chain isotype, and a normal ratio of free light chains in the serum. A partial response was defined as a 50% or greater improvement in quantifiable measures of the plasma cell dyscrasia. For this analysis, follow-up continued for 18 months following drug initiation.
Statistical analysis
Comparisons were made using Fisher's exact test for categorical variables and two-sample t-tests for continuous variables. Analyses used a twotailed significance value of 0.05.
Results
Patient characteristics
Forty-one of the 48 patients enrolled in the trial were included in the analysis. Seven patients were excluded because they were dialysis-dependent at the time of enrolment (n = 2), never received lenalidomide (n = 3) or received <7 days of treatment with lenalidomide (n = 2).
Baseline characteristics of the 41 patients are shown in Table 1 . The majority of patients were male, and most had received prior treatment for AL amyloidosis. Thirty-three patients (80%) had either biopsy-proven or clinically evident renal amyloidosis, and approximately half of the patients had cardiac involvement. Median eGFR and 24 h urinary protein excretion were 69 mL/min/1.73 m 2 and 4.5 g, respectively.
Kidney dysfunction
Kidney dysfunction occurred in 27 of the 41 patients (66%) ( Table 2) . Severe kidney dysfunction occurred in 13 of these patients (32%); four of whom required initiation of haemodialysis. Among those with creatinine elevations, the median time from initiation of lenalidomide treatment to kidney dysfunction was 44 days (interquartile range 15-108 days), and 17 patients (63%) had kidney dysfunction within 8 weeks of starting treatment (Figure 1 ). Among the 10 patients who developed kidney dysfunction more than 8 weeks after starting the drug, the increase in serum creatinine occurred within an 8-week period in 7 (70%). Thus, for 24 of 27 patients (89%), the kidney dysfunction-defining increase in serum creatinine occurred within an 8-week period. Five patients [4, 6, 8, 18, 20] met the criteria for kidney dysfunction but had a peak creatinine concentration that was within or only slightly above the 'normal' range for the laboratory. The eGFRs corresponding to the peak creatinine concentrations for these patients were 68, 66, 52, 42 and 78 mL/min/1.73 m 2 , respectively. Twelve of the 27 patients (44%) had recovery of kidney function (Table 2) . Only one patient with severe kidney dysfunction had recovery, and none of the patients who required initiation of dialysis was able to discontinue dialysis. Renal recovery occurred in seven patients after lenalidomide discontinuation or dose reduction and in five patients who continued the drug without a change in dose. Among the 12 patients with recovery of kidney function, 9 had a second episode of kidney dysfunction during lenalidomide treatment. In three of these patients, the second episode occurred while receiving a lower dose of lenalidomide.
Patients with severe kidney dysfunction were older, had greater urinary protein excretion, had lower serum albumin and had a higher frequency of underlying renal amyloidosis (Table 3) . There was not an apparent relationship between baseline eGFR and development of kidney dysfunction. A potential precipitating event for acute kidney injury was identified in three patients. The events included myocardial infarction in one patient and hypotension in two patients.
For many patients, kidney dysfunction occurred before the haematologic response to treatment was either assessed or expected to be evident making it difficult to evaluate relationships between haematologic disease activity and kidney dysfunction. Among the 21 patients for whom haematologic response was assessed at the time of kidney dysfunction, a complete or partial response was evident in eight patients (38%). Ultimate attainment of a partial or complete response occurred in 10 of the 27 patients with kidney dysfunction (37%).
Discussion
We observed kidney dysfunction, defined as a 50% increase in serum creatinine, in approximately two-thirds of patients receiving lenalidomide for AL amyloidosis. Severe kidney dysfunction, defined as a doubling of serum creatinine, occurred in 32% of patients, and 10% required initiation of haemodialysis. Patients with severe kidney dysfunction were older, had lower serum albumin, had higher urinary protein excretion, and were more likely to have underlying renal amyloid disease than those without severe kidney dysfunction. Recovery of kidney function, defined as creatinine within 25% of the baseline value, occurred in less than half of the patients, and none of the patients who required initiation of dialysis had renal recovery. 
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Although underlying amyloid nephropathy may have predisposed or contributed to worsening of kidney function during treatment with lenalidomide, the temporal relationship with drug initiation and the rate of decline of kidney function make it unlikely that progression of underlying amyloid nephropathy was the principal cause of the kidney dysfunction for most patients. Of the 27 patients with kidney dysfunction, 10 developed kidney dysfunction within 4 weeks after starting lenalidomide, and 7 developed kidney dysfunction 4-8 weeks after starting the drug. Thus, 63% of cases of kidney dysfunction occurred within 8 weeks after drug initiation. For most of the patients with Involved organs include the kidney, heart, liver, autonomic nervous system, peripheral nervous system, gastrointestinal tract, lung, mediastinal lymph nodes, spleen and soft tissue. kidney dysfunction, the deterioration in renal function was more rapid than what is typically seen with amyloid nephropathy. We previously found that serum creatinine increased by 10% over a 3-month period and by 30% over a 12-month period in patients with AL amyloidosis-associated kidney disease and active production of amyloidogenic light chains [21] . In contrast,~60% of the patients treated with lenalidomide, including those with eradication or reduction in amyloidogenic light chain production, had a 50% or greater increase in serum creatinine over a 2-month period. Moreover, four of the patients with kidney dysfunction during lenalidomide treatment had no evidence of underlying renal amyloidosis and no identifiable precipitant for kidney dysfunction other than initiation of lenalidomide. Acute kidney injury was not described as an adverse event in initial trials of lenalidomide for multiple myeloma [9] [10] [11] [12] [13] , but alterations in kidney function have been reported in more recent studies [22] . Among 69 patients with relapsed or refractory multiple myeloma, 26% of those with elevated creatinine at baseline and 32% of those with normal creatinine at baseline had a creatinine increase after three cycles of lenalidomide-based treatment [23] . However, the increase was described as minimal and clinically insignificant. In a trial of lenalidomide for metastatic renal cell carcinoma, an elevation in serum creatinine of grade 1 or 2 severity (<1.5 or 1.5-3 times the upper limit of normal, respectively) occurred in 6 of 28 patients (21%), but no additional information about the events was provided [24] .
Patients with AL amyloidosis may be particularly susceptible to renal effects of drugs because of underlying renal impairment as well as haemodynamic alterations resulting from nephrotic syndrome, cardiomyopathy or autonomic neuropathy. The relationship we observed between kidney dysfunction and urinary protein excretion or hypoalbuminaemia is consistent with haemodynamic susceptibility. In another phase 2 trial of lenalidomide for AL amyloidosis, grade 1 or 2 elevations in creatinine occurred in 23% of patients, but details about the patient characteristics, timing or outcome were not provided [15] . An author of the current paper together with investigators from another institution reported severe renal failure during lenalidomide treatment in five patients with plasma cell dyscrasias; three of whom had AL amyloidosis [17] . Four of the five patients required initiation of dialysis. Two of the patients in that report were participants in our trial and are included in the current analysis (Patient 2 and 7 in Table 2 and Figure 1 ). The seemingly more frequent or severe renal impairment associated with lenalidomide among patients with AL amyloidosis compared with other diseases may reflect an interaction between the drug and an abnormal renal substrate. The presence of hypoalbuminaemia in many of the patients raises a theoretical possibility that reduced protein binding increased the toxicity of lenalidomide; however, measurements of drug concentrations were not performed.
Because none of the patients in our trial underwent kidney biopsy during lenalidomide treatment, we are not able to identify underlying processes. In the series of five patients with acute renal failure during lenalidomide treatment referred to above, a kidney biopsy performed in one patient showed tubular atrophy and degenerative changes, but a clear aetiology for the renal failure was not evident [17] , and interpretation of the biopsy may have been hindered by glomerular amyloid deposits. Lenalidomide has anti-angiogenic and pro-thrombotic properties raising the possibility of endothelial injury as a cause of renal failure [17, 25] . Thrombocytopaenia occurred during treatment with lenalidomide in 11 of the 27 patients with kidney dysfunction, but there was not clinically evident haemolysis or a temporal relationship with the creatinine elevation to suggest a thrombotic microangiopathy as the cause of kidney dysfunction.
In our trial, lenalidomide was discontinued or the dose was reduced following the creatinine elevation in approximately three-fourths of patients with kidney dysfunction. As is evident in Table 2 and Figure 1 , all but one of the patients who had lenalidomide continued without an alteration in dose had kidney dysfunction that occurred relatively late (55 days or more) after starting the drug. The one patient with kidney dysfunction that occurred soon after starting lenalidomide but no subsequent alteration in drug dose (Patient 4 in Table 2 and Figure 1 ) had a peak creatinine concentration of only 1.1 mg/dL. Because of the progressive and often fatal nature of AL amyloidosis and the limited treatment options, decisions to discontinue or reduce the intensity of treatment are difficult. Not surprisingly, in this trial, there was a greater tendency to discontinue lenalidomide or reduce the dose of the drug when the creatinine elevation was especially rapid or severe than when it was relatively modest. The lack of a clear relationship between drug discontinuation or dose reduction and renal recovery probably reflects a greater severity of injury among those for whom the drug dosing was altered.
In 2007, the manufacturer of lenalidomide published pharmacokinetic studies indicating that approximately two-thirds of lenalidomide is excreted unchanged by the kidneys and that the dose of lenalidomide should be adjusted based on kidney function (Table 4) [26, 27] . Had these dosing guidelines been available during the period of this study, 9 of the 41 patients (22%) would have received a lower dose of lenalidomide than was administered at the start of treatment, and 21 of 41 patients (51%) would have required a dose reduction during the course of treatment. Among the 27 patients who developed kidney dysfunction, seven (26%) received an initial dose that was higher than what is now recommended. Following the revised dosing guidelines might have lead to fewer cases of renal dysfunction. Lenalidomide and kidney dysfunction 885
In conclusion, we found that alterations in kidney function occur in a substantial proportion of patients with AL amyloidosis during treatment with lenalidomide. The mechanism for the renal impairment is not clear; however, the temporal relationship with lenalidomide initiation, the relatively rapid deterioration in kidney function, and the absence of other identifiable precipitants for most of the patients suggest that lenalidomide is playing a role. We recommend frequent monitoring of serum creatinine during lenalidomide treatment for AL amyloidosis. Because lenalidomide excretion is dependent on kidney function, dose reduction may be necessary if renal dysfunction occurs. Temporary or permanent discontinuation of lenalidomide should be considered if other causes for deterioration in renal function are not evident.
